Abstract
Author(s): Ahmed Hameed Alsaeedi*, Saif Sami Jaber, Zainab Ali Hussein, Hajer Alaa Obeid, Saif M. Hassan
Women’s health has historically been underrepresented in pharmaceutical research, leading to significant health disparities, especially concerning reproductive health, cardiovascular diseases, and mental health. This paper explores the intersection of women’s health and the pharmaceutical industry, emphasizing the importance of gender-inclusive clinical research and targeted pharmaceutical interventions. The study involves 200 female participants and evaluates the effectiveness of pharmaceutical interventions aimed at addressing conditions disproportionately affecting women, such as hormonal imbalances, mental health disorders, and chronic diseases. Key findings indicate that these interventions significantly improve hormonal regulation and weight management in women, with notable improvements in hormone levels and a modest reduction in body weight in the treatment group compared to the placebo. Additionally, the study highlights the importance of gender-specific approaches in medical research, suggesting that pharmaceutical companies should prioritize research that addresses the unique physiological and psychological needs of women. Despite progress, challenges remain in ensuring equitable representation of women in clinical trials, particularly for conditions like heart disease and menopause, which exhibit gender-specific symptoms and progression. The study calls for continued efforts to improve women’s representation in clinical research to enhance the safety, efficacy, and relevance of treatments developed for women.